CytoSorbents Corp., a Monmouth Junction-based immunotherapy company, announced this week that Chief Medical Officer Dr. Eric Mortensen is leaving at year-end.
Mortensen, whose contract is up at the end of the year, has been with CytoSorbents for more than two years, leading an eight-person U.S. clinical team, the company said.
“Since joining the company two and a half years ago, Eric has leveraged his extensive industry expertise in clinical trials, medical affairs and reimbursement to make numerous contributions to the company,” CEO Dr. Phillip Chan said in a prepared statement.
CytoSorbents’ key product is its CytoSorb blood purification technology to treat deadly inflammation in critically ill or cardiac surgery patients.
Mortensen’s future plans were not disclosed.
